Abstract:
Rationale: Traumatic brain (TBI) injuries result in profound local hypoperfusion, ischemia, chronic inflammation, and metabolic dysregulation which restrict drug delivery to the site of impact so that peripheral treatment alone would have limited access to the site of injury during the most critical phases of neurotrauma. Cannabidiol (CBD), the major non-psychotropic cannabinoid, has anti-convulsant, anti-inflammatory, anti-nociceptive, antioxidant, and immuno-suppressive properties. We hypothesized that continuous local delivery of CBD extracts containing an optimal dose of tetrahydrocannabidol (THC) (CBD:THC) directly to the contusion site overlying the dura of brain would attenuate the risk of excitotoxic Ca2+ hyperexcitability that causes progressive cell death leading to long-term behavioral and neuropathological sequelae, such as paralysis, locomotor impairment, memory and attention deficits, depression, drug abuse, as well as onset to intractable seizures, post-traumatic epilepsy (PTE). Previously we observed that our dual dispensary system of CBD extract reduced lesion volume and restored vestibulomotor and cognitive clinical functions. To determine whether CBD containing an optimal concentration ratio of THC has superior behavioral and neuroprotective effects than CBD lacking THC, four CBD:THC extracts at varied ratio concentrations were compared with CBD derived from hemp (CBDh) lacking THC in our pre-clinical TBI pre-clinical model. Methods: A controlled weight drop stereotactic apparatus was implemented to induce cortical contusion injury (CCI). The beam balance, alternating T-maze, and object recognition tests were used for vestibulomotor and cognitive functions. The forced swim test and elevated plus maze (EPM) were used to measure coping strategy. Brains were evaluated histologically with hematoxylin and eosin and immunohistochemically with NeuN, GFAP, and parvalbumin (PV). Results: Performance on all tests was restored to a greater degree with any of the CBD:THC extracts compared to CBDh, one being more efficacious than the other. Only the TBI untreated group exhibited significant reduction in spontaneous alternation; the highest alternation rates were observed with CBD:THC extract treatments. Time spent with novel objects was also greater with CBD:THC, exhibiting a similar index ratio as sham controls. Although CBDh treated rats spent more time with objects than the TBI group, the amount of time spent with novel and familiar objects was equal thereby lacking recognition discrimination. In the EPM, sham animals spent most of the time in open arms, TBI and CBDh groups spent most of the time in the closed arms, and the CBD:THC groups spent similar time in closed and open arms. In the FST, reduced floating was observed with CBD:THC at 300-10:1 ratio than TBI alone. Lesion volume and gliosis were reduced, and hippocampal sparing was also greatest with the CBD:THC extracts. Concomitant reduction in parvalbumin interneuron labeling was observed not only within the hippocampus on the side of contusion but also within the contralateral hippocampus. With CBDh and CBD:THC extracts, PV cell counts were similar to control counts on the contralateral side and partly restored ipsilaterally suggesting that CBD was responsible for their rescue. Increasing THC and reducing CBD concentrations (1:20-100) resulted in early onset to spontaneous seizures post-TBI.
Biography
Dr. Linda K Friedman, Associate Professor of Neuroscience, New York Medical College, grew up in Massachusetts and received her Bachelor’s degree from the University of Louisville in 1980. She obtained her MA and PhD degrees from the City University of New York, Mount Sinai in 1988. She was a postdoc at Downstate Medical Center, Brooklyn and at Albert Einstein College of Medicine in 1988-1994 and was appointed Instructor Professor in 1994-1996. She was appointed to Assistant and Associate Professor at NJ Neuroscience Institute Seton Hall University 1997-2012, then transferred to New York Medical College in 2012 to present. She has focused on pre-clinical models to study neurotoxicity, delayed neurodegeneration, novel drug therapy, that may lead to neuroprotective and cognitive benefits. She has many awards and honors: 1992, 1997, Annual American Epilepsy Society, Seattle, Junior Investigator Awardee; Red Ribbon Best Poster Award in Basic Research at the 114th Annual Osteopathic Association Convention. 2012, Platform Presentation Selection: Annual American Epilepsy Society Convention. Chosen in Top 10%; 2021: Platform Presentation Selection: “Chronic postnatal subconvulsive activity alters mood, cognition, seizure severity, NeuN antigenicity and polyphosphoinositide hydrolysis within limbic structures of juvenile rats”. Friedman LK, Tenth International Meeting on Metabotropic Glutamate Receptors. Taormina Sicily-Italy.